Table 4.
Additional outcome variables
| Author | Median number of PIPAC procedures (number of patients) | Median number of PIPAC procedures in bidirectional treated patients | CTCAE Reporting | Total | Mono | Bidirectional | Objective tumor response reported | Scale used to report objective tumor response |
|---|---|---|---|---|---|---|---|---|
| Alyami et al. [27] | 2 (n = 73)a | NR | CTCAE reported | Yesc | No | No | Yes | PCI |
| Time frame (days) | 30 | |||||||
| Grade 1-2 | NR | |||||||
| Grade 3-4 | 16 | |||||||
| Grade 5 | 5 | |||||||
| Demtröder et al. [28] | 3 (n = 17)a | NR | CTCAE reported | Yesd | No | No | Yes | TRG |
| Time frame (days) | NR | |||||||
| Grade 1-2 | 12 | |||||||
| Grade 3-4 | 4 | |||||||
| Grade 5 | 0 | |||||||
| Falkenstein et al. [29] | 1 (n = 13)a,b | NR | CTCAE reported | Yesd | No | No | Yes | TRG, PCI |
| Time frame (days) | NR | |||||||
| Grade 1-2 | 9 | |||||||
| Grade 3-4 | 0 | |||||||
| Grade 5 | 0 | |||||||
| Graversen et al. [30] | 3 (n = 5)a | 3 (n = 1)a | CTCAE reported | Yes | No | No | Yes | PRGS, RECIST |
| Time frame (days) | NR | |||||||
| Grade 1-2 | NR | |||||||
| Grade 3-4 | NR | |||||||
| Grade 5 | 0 | |||||||
| Hilal et al. [31] | NR | NR | CTCAE reported | No | No | No | No | NR |
| Khomyakov et al. [24] | 1 (n = 31)a | 1 (n = 31)a | CTCAE reported | Yesd | - | Yes | Yes | PRGS |
| Time frame (days) | 30 | 30 | ||||||
| Grade 1-2 | 3 | 3 | ||||||
| Grade 3-4 | 1 | 1 | ||||||
| Grade 5 | 0 | 0 | ||||||
| Khosrawipour et al. [32] | 1.5 (n = 20)a,b | 1 (n = 6)a | CTCAE reported | Yesd | Yes | Yes | Yes | TRG, PCI |
| Time frame (days) | NR | NR | NR | |||||
| Grade 1-2 | 6 | 3 | 3 | |||||
| Grade 3-4 | 0 | 0 | 0 | |||||
| Grade 5 | 1 | 1 | 0 | |||||
| Nadiradze et al. [33] | 2 (n = 24)a | NR | CTCAE reported | Yesd | No | No | Yes | Unspecified histological regression |
| Time frame (days) | NR | |||||||
| Grade 1-2 | 15 | |||||||
| Grade 3-4 | 7 | |||||||
| Grade 5 | 2 | |||||||
| Reymond et al. [34]a | 4 (3)a | 7 (n = 1)a | CTCAE reported | Yesd | Yes | Yes | Yes | PRGS, RECIST |
| Time frame (days) | NR | NR | NR | |||||
| Grade 1-2 | 3 | 2 | 1 | |||||
| Grade 3-4 | 0 | 0 | 0 | |||||
| Grade 5 | 0 | 0 | 0 | |||||
| Robella et al. [26] | 3 (n = 14)a | 3 (n = 13)a | CTCAE reported | Yesd | No | No | No | NR |
| Time frame (days) | NR | |||||||
| Grade 1-2 | 14 | |||||||
| Grade 3-4 | 0 | |||||||
| Grade 5 | 0 | |||||||
| Farinha et al. [35] | NR | NR | CTCAE reported | No | No | No | No | NR |
| Hübner et al. [36] | NR | NR | CTCAE reported | No | No | No | No | NR |
CTCAE Common Terminology Criteria for Adverse Events, NR not reported, PCI Peritoneal Cancer Index, RECIST Response Evaluation Criteria in Solid Tumors, PRGS Peritoneal Regression Grading Score, TRG Tumor Regression Grading
amedian calculated from presented data
bmean reported in this publication
creported per procedure
dreported per patient